A5089023234- Blood transfusion and management
- Mesenchymal stem cell research
- Platelet Disorders and Treatments
- Blood donation and transfusion practices
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Neonatal Health and Biochemistry
- Pancreatic function and diabetes
- Acute Ischemic Stroke Management
- Erythrocyte Function and Pathophysiology
- Dermatologic Treatments and Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Hemostasis and retained surgical items
- Heme Oxygenase-1 and Carbon Monoxide
- Blood properties and coagulation
- Facial Rejuvenation and Surgery Techniques
- Venous Thromboembolism Diagnosis and Management
- Chemotherapy-related skin toxicity
- Effects of Radiation Exposure
- Iron Metabolism and Disorders
- Diabetes Treatment and Management
- Intramuscular injections and effects
- Diet, Metabolism, and Disease
- MicroRNA in disease regulation
- Ethics and Legal Issues in Pediatric Healthcare
- Blood groups and transfusion
Japanese Red Cross Society, Japan
2015-2025
Zacros (Japan)
2023
Refractoriness to platelet transfusion is a major problem in small group of patients, and large-scale manufacturing clinical grade functional platelets ex vivo has remained an elusive goal. Sugimoto et al report on the results first trial autologous induced pluripotent stem cell (iPSC)-derived patient who had severe aplastic anemia but no compatible donor. Using methodology described complementary article Blood Advances, provide proof-of-principle illustrate challenges be faced taking this...
Abstract Donor-derived platelets are used to treat or prevent hemorrhage in patients with thrombocytopenia. However, ∼5% more of these complicated alloimmune platelet transfusion refractoriness (allo-PTR) due alloantibodies against HLA-I human antigens (HPA). In cases, from compatible donors necessary, but it is difficult find such for rare HPA. To produce products aplastic anemia allo-PTR HPA-1 mismatch Japan, we developed an ex vivo good manufacturing process (GMP)–based production system...
The efficacy of hematopoietic stem cell (HSC) therapy for cerebral infarction has been previously demonstrated. However, the lack response in some patients hindered its widespread use. To establish HSC as a standard treatment, it is important to examine causes non-responsiveness. In this study, we aimed identify specifications transplanted cells based on their therapeutic mechanisms predict treatment success. We found that activates injured endothelial via gap junctions because adhesion...
Currently, the quality of platelet (PLT) products is evaluated using a series in vitro tests, which only analyse PLTs as an inspection material. However, it would be ideal to assess physiological functions under conditions similar sequential blood haemostatic process. In this study, we attempted establish system where thrombogenicity PLT was presence red cells (RBCs) and plasma microchamber constant shear stress (600/s).Blood samples were reconstituted by mixing products, standard human...
Abstract Although regenerative therapy with stem cells is believed to be affected by their proliferation and differentiation potential, there insufficient evidence regarding the molecular cellular mechanisms underlying this effect. We recently found that gap junction-mediated cell–cell transfer of small metabolites occurred very rapidly after cell treatment in a mouse model experimental stroke. This study aimed investigate whether tissue repair ability umbilical cord blood X-irradiation at...
We have previously demonstrated that small molecular transfer, such as glucose, between hematopoietic stem cells (HSCs) or mesenchymal (MSCs) and vascular endothelial via gap junctions constitutes an important mechanism of cell therapy. Cell metabolites are high-potential small-molecule candidates can be transferred to molecules cells. Here, we investigated the differences in metabolite levels (HSCs MSCs), cells, circulating non-hematopoietic white blood (WBCs). The results showed remarkable...
The total thrombus-formation analysis system (T-TAS) can quantitatively analyse the contribution of platelets to haemostasis using reconstituted blood samples. However, it is unsuitable in cases with low platelet counts. We introduced a haemodilution (HD) chip shallow chamber depth, adapted counts and high shear conditions (1500 s
Abstract Background and Objectives Quantifying the contribution of individual coagulation factors to haemostasis may aid our understanding haemostatic function in patients with rare deficiencies (RCDs) exploration suitable treatments. Materials Methods Reconstituted blood prepared from specific factor‐deficient plasma (factor [F]II; prothrombin, FV, FVII, FVIII, FIX, FX, FXI or FXII) red cell/platelet products were used simulate whole RCD. We vitro treatment models for prothrombin deficiency...
融解した新鮮凍結人血漿（FFP）は，温度に不安定な凝固因子活性が経時的に低下することが海外で報告されているが，凍結融解を繰り返したFFPの品質変化を評価した報告はない．そこで400 ml全血採血由来FFPについて3回凍結融解時の品質評価を行った．凍結融解を繰り返すことにより第V因子活性，第VIII因子活性は低下し，活性化部分トロンボプラスチン時間は延長する傾向を示したが，pH，ナトリウム濃度，カリウム濃度，プロトロンビン時間，フィブリノゲン濃度，第II因子活性，第VII因子活性，第XI因子活性，フォンヴィレブランド因子リストセチンコファクター活性に有意な変化はみられなかった．3回目凍結融解FFPのプロトロンビン時間は11.3±0.7 secで，生物学的製剤基準の凝固試験の判定基準である20 sec以下を保持し，第VIII因子活性は0.72±0.23 IU/mlとEUガイドライン（0.70...
Washed platelet concentrates (WPC), prepared with an automated system cell processor (ACP), have recently been approved to be manufactured and marketed in Japan. From the perspective of risk management, it is preferable secure alternative technologies for ACP. Here, we conducted a study evaluate quality WPC using membrane filtration-based system, Lovo.Replaced PCs from apheresis were equally divided into control test units, subsequently washed ACP Lovo respectively. Work operational...
今般，安定的な血小板製剤（PC）の確保を目的とし，成分採血装置Trima Accelに，一人の献血者から2本分の10単位PCを一度に採血できるプログラムが搭載された．この採血方法では従来の方法と異なり，一つのポリ塩化ビニル製採血バッグ（PVCバッグ）に通常の2倍量の血小板原料が入る．さらに，その状態で採血当日または翌日まで保管後，2分割する必要がある．本検討では，採血翌日に分割した分割対象血小板原料血液由来10単位PC（分割PC）の品質を解析した．
FVIII)因子活性は，血液製剤の使用指針に記載されているが，その他の凝固因子について報告はない． そこで，成分由来 FFP(FFP480)と全血由来 FFP(FFP240)の品質評価を凍結前と凍結保存後(1-13 カ月)に 行った． 保存 12 カ月において， 凍結前活性値を 100 とした相対値で FFP480， FFP240 ともに 90 を下回った凝固因子は FVIII
血小板製剤（PC）による輸血副作用防止にはPCの洗浄が有用だが，通常，これには大型遠心機を用いたPC洗浄（遠心法）が行われる．一方，血液透析や血漿交換など医療機関における血液浄化療法では，中空糸膜を用いた血球と血漿の分離が一般的である．
解凍赤血球液（Frozen-Thawed Red Cells：FTRCs）は，中間製品である凍結赤血球液（Frozen Cells：FRCs）として10年間保存可能であるため，まれな血液表現型を持つ患者にとって有用な血液製剤である．しかしながら，FTRCsは，凍結・融解工程に起因する溶血により，製品規格である総ヘモグロビン（Haemoglobin：Hb）含有量を満たさない場合がある．本研究では凍結工程に着目し，溶血を抑制することでFTRCsのHb含有量の向上を目指した．採血5日目（5-day-old：5D）または9週目（9-week-old：9W）の赤血球液（Red Blood Cells：RBCs）をグリセロール化し，プーリング後に2分割した．グリセロール化RBCsはプログラムフリーザー（Programmed Freezer：PF）法またはディープフリーザー（Deep...
【背景と目的】現在，血小板（Platelet：PLT）製剤の品質評価は，検査材料としてのPLTのみを分析する一連のin vitro試験で行われている．しかしながら，連続的な止血過程に近い条件下でPLT生理機能を評価することが理想的である．そこで本研究では，マイクロチャンバーを用いて，一定のせん断応力（600/s），赤血球（Red blood cell：RBC）および血漿の存在下，PLT製剤の血栓形成能を評価するin vitroシステムの開発を試みた．
現在，照射解凍赤血球液は赤血球液から解凍赤血球液製造後にX線照射して調製する方法と，照射赤血球液から調製する2種類の方法で製造されている．両者はX線照射を解凍後に実施するか，凍結前に実施するかで異なる．X線照射は赤血球膜障害を引き起こすことが知られており，照射時期の違いで照射解凍赤血球液のヘモグロビン回収率に差があれば，優れた製造方法を採択することが望ましい．本検討では同一原料血液を用いて，照射時期の異なる2種類の製造方法より照射解凍赤血球液を製造して品質データを比較した．その結果，ヘモグロビン回収率及び溶血率は照射時期の違いによる差を認めず，上清カリウムイオン濃度は照射時期により差を認めたものの，通常の輸血では両製造法とも問題のないレベルであった．
Frozen-thawed red blood cells (FTRCs) are useful components to patients with rare phenotypes. However, frozen (FRCs) sometimes cause significant haemolysis after thawing due the freeze/thaw process. In this study, we aimed focus on former process and reduce process-related haemolysis.Five-day-old (RBCs) (5D) or 9-week-old RBCs (9 W) were glycerolized, pooled split into two aliquots. using either programmed freezer (PF) method deep (DF) method. After 4-8 weeks, FRCs thawed washed. vitro...